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The hormonal milieu influences immune tolerance and the im-
mune response against viruses and cancer, but the direct effect of
androgens on cellular immunity remains largely uncharacterized.
We therefore sought to evaluate the effect of androgens on
murine and human T cells in vivo and in vitro. We found that
murine androgen deprivation in vivo elicited RNA expression
patterns conducive to IFN signaling and T-cell differentiation.
Interrogation of mechanism showed that testosterone regulates
T-helper 1 (Th1) differentiation by inhibiting IL-12–induced Stat4
phosphorylation: in murine models, we determined that androgen
receptor binds a conserved region within the phosphatase, Ptpn1,
and consequent up-regulation of Ptpn1 then inhibits IL-12 signal-
ing in CD4 T cells. The clinical relevance of this mechanism,
whereby the androgen milieu modulates CD4 T-cell differentia-
tion, was ascertained as we found that androgen deprivation re-
duced expression of Ptpn1 in CD4 cells from patients undergoing
androgen deprivation therapy for prostate cancer. Our findings,
which demonstrate a clinically relevant mechanism by which
androgens inhibit Th1 differentiation of CD4 T cells, provide ratio-
nale for targeting androgens to enhance CD4-mediated immune
responses in cancer or, conversely, for modulating androgens to
mitigate CD4 responses in disorders of autoimmunity.
immunomodulation | cancer immunotherapy | prostate neoplasm
The sex-specific hormones, testosterone and estrogen, havea number of immuno-modulatory effects. Women almost
universally respond as well or better than men to antibody-inducing
vaccinations (1). For example, healthy women treated with the
trivalent inactivated influenza vaccine generate a greater antibody
titer than men (2). Findings like these have led to the suggestion
that estrogen promotes T-helper 2 (Th2) differentiation and an-
tibody production (3). Further supporting an increased antibody
response caused by estrogen, more than 80% of patients suffering
from antibody-driven autoimmunities such as systemic lupus
erythematosus, Sjörgren syndrome, and Hashimoto thyroiditis
are women (4). In contrast to estrogen, how testosterone affects
the immune system is less clear, but its role in immunity against
viruses and host antigens is certainly immunosuppressive.
Recently, it was reported that testosterone levels negatively
correlated with the antibody response to the trivalent inactivated
seasonal influenza vaccine by interfering with lipid metabolism
(5). Testosterone levels are also positively correlated with the
viral load of Venezuelan equine encephalitis virus in macaques
(6). In addition to the response to viruses, testosterone regulates
the response to host antigens in many biological systems. Ele-
vated levels of testosterone following colonization with com-
mensal microbes correlated with reduced islet inflammation and
protection from type 1 diabetes in nonobese diabetic mice (7).
Also, tolerance to tumor antigens is regulated by testosterone, as
androgen ablation in a mouse model of prostate cancer re-
versed CD4 T-cell tolerance to a prostate restricted tumor antigen
(8). Similarly, castration of male mice before vaccination with
prostate-specific antigens enhanced CD8 T-cell vaccine response
in many studies (9, 10). Patients undergoing androgen depriva-
tion in prostate cancer had increased infiltration of T cells into
benign and malignant prostate tissue (11). Based on these find-
ings, clinical trials are currently underway to test the combina-
torial efficacy of androgen deprivation and immunotherapy in
prostate cancer patients (12). Together, these observations sug-
gest a critical role for testosterone in maintaining T-cell toler-
ance toward not only viruses, but also host and tumor antigens.
Despite these observations that testosterone inhibits immu-
nity, the precise molecular mechanisms by which testosterone
achieves this effect are poorly understood. Here, we sought to
address this question by performing gene expression profiling of
CD4 T cells isolated from castrated mice. Gene expression
analysis revealed a critical effect of testosterone on CD4 T-cell
differentiation and identified protein tyrosine phosphatase
nonreceptor type 1 (Ptpn1) as a mediator of androgen-induced
suppression of CD4 T-cell differentiation. The research presented
here highlights a previously unreported molecular mechanism by
which testosterone suppresses immunity and allows a better un-
derstanding of sex differences in the response to viruses, autoim-
munity, and immune escape in prostate cancer.
Results
Gene Expression Profiling of CD4 T Cells Isolated from Castrated Mice
Reveals Altered Differentiation and Signaling. To investigate the
molecular mechanisms by which androgen withdrawal affects the
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T-cell response to self-antigens, gene expression of CD4 T cells
isolated from the spleens of surgically castrated or control mice
was profiled using Affymetrix microarrays. Of the 1,037 twofold
differentially expressed genes, 637 were down-regulated and 400
were up-regulated following castration. Using the Ingenuity
Pathway Analysis (IPA) software package, we found that the two
most significantly altered pathways within those differentially
regulated were IFN signaling and T-helper cell differentiation
(Fig. 1A). About half of the genes that constitute these two
pathways were differentially expressed. In particular, numerous
genes related to Th1 differentiation such as T-bet, IL-12R, and
IFN-γ were up-regulated (Fig. 1B). To confirm these microarray
findings, expression of key CD4 T-cell differentiation genes was
measured by RT-PCR. Consistent with the microarray analysis,
a significant increase in expression of T-bet and IFN-γ was ob-
served, whereas no change was observed for the other master
transcription factors involved in CD4 T-cell differentiation,
Gata-3, Foxp3, and Ror-γt (Fig. 1C), suggesting that differenti-
ation of CD4 T cells into the Th1 phenotype was preferentially
affected. Expression of the Th1 surface markers CXCR3, CCR5,
and IL-12Rb2 were analyzed. CXCR3 was significantly increased
in CD4 cells in castrated mice, whereas the other two markers
were unchanged (Fig. S1). Additionally, analysis of upstream
transcription factors responsible for the observed gene changes
predicted significant activation of the Th1-related transcription
factors IRF-1, -3, and -7 and signal transducer and activator of
transcription 1 (STAT1) in castrated CD4 T cells (Table S1).
These data suggest that important signaling pathways and gene
expression regulatory networks orchestrating Th1 differentiation
are altered following castration.
Testosterone Inhibits Th1 Differentiation In Vitro. T-helper cell dif-
ferentiation is a critical junction of an immune response, and
Th1 differentiation is particularly important in the case of the
response to self- and tumor antigens (13). Following the in silico
identification of the major disruptions to Th1 differentiation by
androgen deprivation, we sought to further investigate the effect
of androgen on this differentiation pathway in vitro. CD4 T cells
isolated from spleens of male mice were incubated overnight in
androgen-free culture medium. These cells were then cultured
under Th1 polarizing conditions in the presence of the androgen
analog R1881 or vehicle control and then restimulated with
phorbol myristate acetate/ionomycin 3 d later. We found that
CD4 T cells treated with androgen produced significantly less
IFN-γ as measured by intracellular flow cytometry (Fig. 2 A and
B). To determine whether this was due to inhibition of Th1
differentiation or the recall response, IFN-γ production was
measured in cells differentiated without androgen but restimu-
lated in its presence. These cells produced the same amount of
IFN-γ as cells that were not exposed to androgen, indicating that
androgen inhibited IFN-γ production before restimulation.
Similarly, IFN-γ production by cells differentiated for 3 d in the
presence of androgen, but restimulated overnight in androgen-
free media produced the same amount of IFN-γ as cells both
differentiated and restimulated in the presence of androgen,
suggesting that androgen inhibition of IFN-γ production by CD4
T cells occurs during the Th1 differentiation phase. To further
investigate the effect of androgen on T-cell differentiation, RNA
was isolated from cells differentiated in androgen or vehicle
control before PMA/ionomycin stimulation. Consistent with
the in silico analysis, CD4 T cells differentiated in the pres-
ence of androgen had significantly reduced levels of T-bet and
IFN-γ (Fig. 2C). Together, these data suggest that androgen
exerts its effect on T cells during the early events involved in
Th1 differentiation.
Testosterone Inhibits IL-12–Induced STAT4 Phosphorylation and
Downstream Gene Expression. Because Th1 differentiation critically
relies on IL-12–induced phosphorylation of STAT4, we analyzed
this protein in CD4 T cells treated with IL-12. STAT4 phos-
phorylation was reduced in CD4 T cells treated with androgen 30
min following IL-12 exposure. The androgen-treated cells still
Fig. 1. Th1 differentiation is enhanced in castrated mice. (A) Significantly altered pathways in CD4 cells isolated from castrated mice. Genome-wide gene
expression profiling of CD4 T cells isolated from the spleen of male mice 1 mo following castration was performed and significantly altered signaling
pathways determined using the Ingenuity Pathway Analysis package. (B) Genes changed in CD4 T-cell differentiation pathways. CD4 T-cell differentiation
pathway was found to be significantly altered in castrated mice and differentially expressed genes associated with these pathways are shown. (C) PCR
confirmation of important differentiation genes. Gene expression of important differentiation regulators/markers in CD4 T cells isolated from sham (●) or
castrated mice (■) was measured by RT-PCR. Data combined from two separate experiments are shown.
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showed a slight reduction in STAT4 phosphorylation 60 min
following IL-12 treatment. However, after 24 h, cells treated with
androgen or vehicle had equal levels of pSTAT4 (Fig. 2D). Be-
cause insufficient induction of pSTAT4 during CD4 T-cell ac-
tivation can lead to T-cell anergy or induction of regulatory
T cells (14), we hypothesized that testosterone may increase the
threshold of IL-12 required to induce Th1 differentiation. CD4 T
cells were cultured under Th1 polarizing conditions with in-
creasing concentrations of IL-12 either in the presence of 1 ng/mL
R1881 or vehicle control, and the expression of T-bet was assessed
3 d later. R1881 treatment resulted in significantly less T-bet ex-
pression in CD4 T cells receiving 0, 3.125, and 12.5 ng/mL of
IL-12 (Fig. 2E). However, at the higher concentrations of IL-12
(25–100 ng/mL), androgen had no significant effect on T-bet ex-
pression. These data support the notion that Th1 differentiation is
inhibited in the presence of androgen and also that CD4 Th1
polarization is specifically impaired in low IL-12 conditions via
a reduction in STAT4 phosphorylation.
Castration of Mice Leads to Increased T-Cell Infiltration in Lung,
Prostate, and Intestine. Androgen deprivation therapy increases
lymphocyte infiltration in the prostate gland of both mice and
men, and this infiltration is predominantly CD4 T cells (10, 11).
This observation was made in the context of prostate cancer and
omitted evaluating nonprostatic tissue inflammation. Given our
finding that testosterone reduced the amount of IL-12 required
to induce CD4 cell differentiation, we hypothesized that testos-
terone’s effect might extend beyond the prostate. To investigate
this, liver, lung, prostate, and intestine samples were collected
from male mice 1 mo following surgical castration and stained
for CD3 expression. We found a significant increase in the
number of CD3+ cells in the prostate gland (4-fold) and lungs
(2.5-fold). Infiltration in the prostate was mostly found in the
peripheral zone (Fig. S2). Additionally, a nonsignificant increase
was observed in the small intestine (P = 0.056; Fig. 2F). The
presence of some sparse and sporadic T-cell infiltrates in tissues
of sham castrated mice indicates the onset of a minimal, spon-
taneous “autoimmune” phenotype, and the significantly increased
presence of T cells in nonprostatic tissues of castrated animals
suggests that testosterone may limit the reactivity of T cells to
host tissue.
Testosterone Up-Regulates the Tyrosine Phosphatase Ptpn1 and
Inhibits Tyk2 Phosphorylation. Many molecules regulate phos-
phorylation of STAT4 following IL-12 exposure. Therefore, we
sought to examine the expression of signal transduction mole-
cules upstream of STAT4 in an attempt to understand how
testosterone inhibits IL-12 signaling. To identify signal trans-
duction components that may be regulated by testosterone, we
searched for genes with opposite expression in CD4 T cells ex-
posed to high or low testosterone conditions by comparing CD4
T cells isolated from castrated mice to testosterone treated CD4
T cells in vitro. We found that the genes encoding protein ty-
rosine phosphatase nonreceptor 1 and 11 (Ptpn1 and Ptpn11)
were significantly decreased in castrated mice and significantly
up-regulated in androgen treated CD4 T cells, suggesting that
the expression of these phosphatases is regulated by testosterone
(Fig. 3 A and B). Candidate genes from the SOCS, PIAS, and Jak
family of molecules were affected in one condition but not the
other (Dataset S1). These data suggest that, although androgen
seems to exhibit diverse effects on T-cell signaling, only Ptpn1
and Ptpn11 were directly controlled by the presence of androgen
under our experimental conditions.
To investigate whether androgen directly affects expression of
Ptpn1 and Ptpn11, CD4 T cells were treated overnight with
androgen, and Ptpn1 and Ptpn11 gene expression was analyzed.
We found that Ptpn1 was significantly up-regulated (1.7-fold),
whereas no significant difference in Ptpn11 expression was seen
(Fig. 4C). To further understand how androgen regulates ex-
pression of Ptpn1, we investigated publically available gene ex-
pression profiling datasets involving testosterone treatment to
find how Ptpn1 expression was affected in other cell types and
conditions. Ptpn1 was found to be unchanged or up-regulated by
testosterone exposure in all datasets examined, including human
prostate cancer cell lines, mouse adipose tissue, and mouse
lacrimal and submandibular glands (Fig. 3D). These data show
that Ptpn1 expression is regulated by androgen in numerous cell
types, including lymphocytes.
Fig. 2. Th1 differentiation is inhibited by testosterone in vitro. (A and B) IFN-γ production by CD4 cells differentiated with testosterone. Spleen CD4 T cells
were cultured under Th1 polarizing conditions and treated with the androgen receptor agonist R1881 or vehicle control. Representative plots of IFN-γ
production measured by flow cytometry after restimulation with PMA/Ionomycin. Mean ± SD of IFN-γ production after Th1 differentiation and restimulation
in the presence of R1881 or vehicle for five samples. (C) Gene expression in testosterone treated Th1 cells. Fold change of gene expression of Th1-related
genes from CD4 T-cell differentiation (n = 3). (D) Testosterone effect on Stat4 phosphorylation. CD4 T cells were analyzed for levels of phospho-STAT4 at
different time points following treatment with 5 μg/mL IL-12 in the presence or absence of R1881. (E) Testosterone effect on T-bet expression. T-bet ex-
pression in CD4 T cells after 4 d of culture under Th1 polarizing conditions in the presence or absence of R1881 (n = 5). (F) Castration induces T-cell infiltration
into various tissues in mice. Prostate, lung, and gut specimens were collected from castrated male mice 1 mo following surgical castration and stained for CD3.
Data show mean counts from 10 random fields of view from each sample ± SD. Each sample has three to four mice per group.
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Ptpn1 is a phosphatase that dephosphorylates insulin-like
growth factor 1 receptor (IGFR), Jak2, and Tyk2, thereby in-
hibiting downstream signals triggered by these molecules (15).
Our IPA analysis of CD4 T cells from castrated mice predicted
that the kinase Tyk2 was significantly activated in castrated mice
(Table S1). The up-regulation of Ptpn1 by testosterone, leading
to the dephosphorylation of Tyk2, could explain how androgens
inhibit Th1 differentiation. To investigate this, CD4 T cells were
treated overnight with androgen, and Tyk2 phosphorylation was
measured following administration of IL-12. Strong Phospo-
Tyk2 signal was detected 5 min after IL-12 treatment under
androgen-free conditions. In contrast, androgen-treated cells
had a much lower level of Tyk2 and STAT4 phosphorylation
(Fig. 3E). To investigate the contribution of Ptpn1 to this in-
hibition, cells were treated with a specific Ptpn1 inhibitor for 2 h
before the administration of IL-12. The inhibitor restored the
phosphorylation of Tyk2 and STAT4, suggesting that Ptpn1
induction by testosterone inhibits IL-12 signaling (Fig. 3E).
This finding supports our hypothesis that up-regulation of
Ptpn1 by testosterone leading to the inhibition of Tyk2 phos-
phorylation is a mechanism by which testosterone inhibits
Th1 polarization.
Androgen Receptor Binds a Conserved Region Within Intron 3 of
Ptpn1. Following testosterone binding, the androgen receptor
(AR) is translocated to the nucleus where it associates with an-
drogen response elements (AREs) in the DNA. When bound to
DNA, AR can regulate gene expression by directly initiating
transcription or indirectly altering the epigenetic environment of
the target gene (16). AR was detectable in CD4 cells isolated
from both sham and castrated mice (Fig. S3). To investigate how
androgen affects Ptpn1 expression, we created a search algo-
rithm to identify potential AR binding sites in the Ptpn1 gene
and upstream promoter region. Five putative AR-binding sites
were found in and around the Ptpn1 gene (Fig. 4A). To de-
termine whether AR bound any of these regions, chromatin from
CD4 T cells treated with R1881 or vehicle was immunoprecipi-
tated (ChIP) with an anti-AR antibody, and potential binding
sites were tested by PCR. Interestingly, no significant enrichment
for the predicted AR binding site in the promoter region was
observed. However, the predicted binding site in the intron be-
tween exon 3 and 4 (intron 3) was significantly enriched after
R1881 treatment (Fig. 4A). Because we have observed androgen-
specific down-regulation of Ptpn1 expression in both human and
mouse cells, we assessed the homology of mouse intron 3 among
humans, mice, and three other species. Although the exonic
regions of Ptpn1 were highly conserved across many species,
human and mouse introns rarely showed homology above 50%
(Fig. 4B). However, regions of microhomology, defined as 20-
to 50-bp regions of very high homology (>80%) conserved
across multiple species, were present in some introns (highlighted
in blue in Fig. 4C). One of these regions contained the AR binding
site that we identified in intron 3, and a similar site in the same
intron was also present in rats, Macaca monkeys, and elephants,
suggesting that an evolutionarily conserved role of androgen reg-
ulation of Ptpn1 might exist (Fig. 4C). Together, these data show
that androgen regulates expression of Ptpn1 in numerous cell
types, in both humans and mice, and that a conserved androgen
binding site in the third intron of the Ptpn1 gene may be the
critical regulator of this effect.
CD4 Cells Isolated from Patients Undergoing Androgen Deprivation
Therapy Have Decreased Ptpn1 Expression. Prostate cancer patients
undergoing androgen derivation therapy (ADT) have increase T-
cell infiltration into the prostate gland, and castrated mice have
an improved response to vaccination against tumor antigens (8–
10). Given the homology of the AR binding site between the
mouse and human Ptpn1 gene, we investigated whether Ptpn1
was regulated in a similar way in human T cells in vivo. To do
this, we isolated CD4 T cells from the peripheral blood of
prostate cancer patients undergoing ADT. CD4 T cells from
patients on ADT showed a twofold reduction in Ptpn1 expres-
sion compared with control patients (Fig. 5). In comparison with
mice, there was no significant change in IFN-γ or T-bet expres-
sion in the human CD4 T cells. Additionally, there was no dif-
ference in any other CD4 T-cell transcription factors (Dataset
S1). These data support the conserved function of androgen
receptor regulation of Ptpn1 and may explain the improved T-cell
response to the tumor in ADT patients.
Discussion
Here, we investigated the effect of testosterone on CD4 T-cell
function. Our data suggest that testosterone inhibits CD4 T-cell
differentiation by up-regulating the phosphate Ptpn1. Ptpn1 is an
enzyme that is expressed in many cell types, including lympho-
cytes, and importantly, it dephosphorylates both Jak2 and Tyk2,
the upstream kinases responsible for Stat4 phosphorylation (15,
16). Because Ptpn1 is known to dephosphorylate Tyk2, our data
Fig. 3. Expression of Ptpn1 is regulated by andro-
gens. (A). Gene expression of various cell signaling
components in Th1 CD4 T cells. CD4 cells were cul-
tured in the presence or absence of androgen under
Th1 conditions for 3 d. Gene expression was mea-
sured by quantitative PCR. (B) Effect of testosterone
on Ptpn1 and Ptpn11 in vivo. Expression of Ptpn1
and Ptpn11 in CD4 T cells isolated from spleens of
control or surgically castrated male mice 4 wk post-
surgery (n = 6 and 7, respectively, from two separate
experiments). (C) Direct effect of testosterone on
Ptpn1. Expression of Ptpn1 in murine CD4 T cells
treated with R1881 overnight (n = 3). (D) Effect of
testosterone on Ptpn1 expression in other cell types.
Expression of Ptpn1 from various datasets available
on the GEO where cells had been treated with an-
drogen. Numbers in parentheses indicate dataset GEO
identification numbers. (E) Effect of Ptpn1 on Tyk2
and STAT4 phosphorylation after IL-12 exposure. CD4
T cells were treated with 5 μg/mL IL-12 in the presence
or absence of R1881, with and without treatment
with a Ptpn1-specific inhibitor. CD4 cells were ana-
lyzed for levels of phosph-Tyk2 5 min after treatment.
Blots are representative of two experiments.
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showing testosterone reduced Tyk2 phosphorylation support
this role of Ptpn1. Additionally, Tyk2 phosphorylation could
be partially restored by coadministration of a specific Ptpn1
inhibitor, further suggesting that androgen inhibition of Stat4
phosphorylation and Th1 differentiation is mediated through up-
regulation of Ptpn1. This role of Ptpn1 has not been previously
reported; however, other tyrosine phosphatases, Ptpn6 and
Ptpn11, inhibit Th1 differentiation (17–19). Inhibited Th1 dif-
ferentiation by Ptpn1 has clear implications to the immune re-
sponse and helps explain previous observations that testosterone
limits viral vaccine effectiveness, viral clearance, the response to
host antigens, and the T-cell response to cancer (5–9).
Beyond de-phosphorylating Tyk2, Ptpn1 has many other
known roles and likely contributes to suppression of the immune
system beyond what we have reported. For example, we found
that androgens could also inhibit Th17 differentiation (Fig. S4).
Stat5 is also a substrate for Ptpn1, and Ptpn1 deficiency increases
Stat6 phosphorylation in B cells (20, 21). Additionally, Ptpn1-
deficient mice suffer from systemic inflammation, increased
leukocyte migration, and is a potential molecule in regulating the
allergic response (22). In addition to regulating known pathways
affecting immunity, Ptpn1 has a critical role in regulating me-
tabolism. Ptpn1 regulates both insulin-like growth factor (IGF)
signaling by inhibiting receptor kinases associated with the
receptors of these molecules (23, 24). In addition, there are
a number of SNPs found in Ptpn1 that are associated with
hypertension and obesity (25). One of the critical findings of
a recent report demonstrating the negative correlation of tes-
tosterone and influenza vaccine efficacy was that testosterone
altered lipid metabolism in the immune system (5). Given that
Ptpn1 is a regulator of IGF signaling, it is rational to expect
that testosterone induced expression of Ptpn1 may be associ-
ated with regulation of lipid metabolism, and therefore, could
be one of the mechanisms that leads to reduced influenza
vaccine efficacy by testosterone.
The mechanism of androgen-induced regulation of Ptpn1 ex-
pression was also addressed in this work. Various studies have
demonstrated the presence of AR both in the cytosol and on the
membrane of T lymphocytes (26, 27). We found that there was
an AR binding site in the intron between exon 3 and 4 of the
Ptpn1 gene. However, how the binding of AR to this region in-
creased Ptpn1 expression of the gene is unclear. One possibility
is chromatin modification of this region by factors that associate
with AR (28). The effect of this has been shown recently in ge-
nome wide investigations where AR binding to DNA has been
found to be associated with increased accessibility of the location
and this could be how AR regulates Ptpn1 expression (29).
Others have recently found that AR binds Ptpn1 in human
prostate cancer cells, leading to Ptpn1 expression, although the
binding was at a different location from the one we found (30).
Although these observations implicate AR-mediated expression
of Ptpn1, the question remains of why androgen regulates Ptpn1.
We found that the AR binding site was highly conserved
among numerous species within a region of very low homol-
ogy, indicating that the regulation clearly has some evolu-
tionary importance. Why males need to be more protected
from autoimmunity is unclear. Others have offered plausible
speculation that the evolutionary role of testosterone-mediated
immune suppression may be to protect men from pathogen ex-
posure during traumatic injury, for which in many species the
males are more likely to suffer (5). Our data suggest an addi-
tional possibility: that because the role of Ptpn1 is important in
metabolism regulation and IGF1 signaling (31), testosterone
regulation of Ptpn1 is more important for these processes, and
the effect of testosterone on the immune system either directly
or by altered lipid metabolism may be a bystander effect. None-
theless, testosterone does contribute to expression of Ptpn1 in
multiple cell types and species, and in T cells, this increase in
Ptpn1 expression reduces the response of the cells to IL-12.
The findings presented here show a potential mechanism to
explain how testosterone alters CD4 T-cell function. We found
that down-regulation of Ptpn1 following castration increased
Th1 differentiation in sterile inflammatory conditions. Further
investigation in vitro found that testosterone limited Stat4
phosphorylation and Th1 differentiation. We propose that these
findings may help explain why testosterone helps alleviate Th1-
driven autoimmune conditions. Furthermore, these findings
support the idea of using ADT as an adjuvant for immunother-
apeutic intervention in prostate cancer and suggest that Ptpn1
targeting could be investigated as an adjuvant for cancer vaccine
against tumor antigens.
Methods
Surgical Castration. C57BL/6J mice were castrated as previously described (9).
Mice were used in experiments 28 d after castration, which was the earliest
Fig. 4. Androgen receptor binds to a region in in-
tron 3 of the Ptpn1 gene. (A) ChIP and quantitative
PCR quantification of AR binding to Ptpn1. Male
mouse spleen CD4 T cells treated overnight with
R1881 or vehicle control. ChIP for androgen re-
ceptor was performed, and fold enrichment was
determined by qRT-PCR of putative AR binding
regions within the Ptpn1 gene. (B) Homology be-
tween species of intron 3 of Ptpn1. Homology of
Ptpn1 between mouse and human or rat. Exon is
shown in red and regions of high homology con-
served between species are shown in blue. (C) DNA
sequence of AR binding region in different species.
Fig. 5. Ptpn1 expression is reduced in CD4 cells isolated from prostate
cancer patients undergoing androgen deprivation. CD4 cells were isolated
from patients undergoing ADT by FACS. Ptpn1 expression in CD4 T cells
isolated from PBMC of prostate cancer patients on androgen deprivation
therapy and control patients; n = 13 and 7.
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time point we previously found to be when androgen-dependent gene ex-
pression is lost (9).
Histology. Trained pathologists at the Beth Israel Deaconess Medical Center
histology core performed tissue sections and immunohistochemistry stain-
ing. Slides were stained using anti-CD3 (134096; Abcam) at a 1:500 dilution and
a secondary Biotin SP-conjugated anti-rabbit IgG diluted 1:250 (711-065-152;
Jackson ImmunoResearch). A microscope operator blinded to the exper-
imental design and staining procedure acquired 10 random fields of view
from each slide. CD3+ cells were counted using an automated counting
algorithm in ImageJ.
Microarray Analysis. CD4Foxp3GFP cells were isolated from mice using FACS.
RNA was extracted, and gene expression was assessed using Affymetrix’s
GeneChip Mouse Genome 430 PM arrays over two separate experiments.
Data can be accessed from the Gene Expression Omnibus (GEO) database,
accession no. GSE54945.
Pathways and Network-Based Analysis. Interactive networks, pathways, and
functions analysis were performed on this list of genes using the commercial
system biology oriented package IPA (www.ingenuity.com).
T-Cell Isolation and Th1 Differentiation. The CD4 T cells isolated from human
and mouse samples used for gene expression analysis were sorted by FACS. A
detailed gating strategy to isolate these cells is shown in Fig. S5. CD4 T cells
used for in vitro experiments were isolated from the spleen of male C57BL/6J
mice using StemCell Technologies CD4 T-cell isolation kit (cat# 19765). To
eliminate the effect of endogenous testosterone, T cells were incubated
overnight in charcoal-stripped media. For Th1 differentiation experiments,
CD4 cells were incubated with anti-CD3/anti-CD28 stimulation beads (Life
Technologies), 5 ng/mL IL-12 (Peprotech), and 10 ng/mL IL-2 (Peprotech). To
investigate the role of androgen, T cells were treated with either 2 ng/mL
R1881 (Perkin Elmer) or DMSO as a vehicle control. Restimulation of T cells
was performed using eBioscience cell stimulation mixture (PMA/ionomycin,
cat#: 00-4979-93). IFN-γ production by CD4 T cells was assessed by flow
cytometry using eBioscience antibodies.
Western Blot. CD4 cells were isolated as described above and incubated
overnight in charcoal-stripped androgen-free media. T cells were treated with
5 ng/mL IL-12, 2 ng/mL R1881, or vehicle control. Experiments investigating the
role of Ptpn1 used the inhibitor 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-
benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide at a con-
centration of 4 μM (cat# 539741; Millipore). Protein was extracted using cell
lysis buffer (Cell Signaling) as described by the manufacturer. Western blot
analysis of pSTAT4 (D2E4) and PTyk2 (Cell Signaling #9321) was performed
following the manufacturer’s protocol. Figures shown are representative of
at least three separate experiments.
Androgen Receptor Binding Site Prediction. Putative androgen receptor
binding sites in the Ptpn1 gene were determined by searching the mouse
Ptpn1 gene for regions of high similarity to the androgen response element I
sequence AGAACANNNAGTGCT.
Ptpn1 Homology. Homology between species was determined by comparing
the similarity of the mouse Ptpn1 gene to the human Ptpn1 gene using
a custom python script. Briefly, the mouse and human Ptpn1 genes were
subdivided into 300-bp frames. These fragments of the mouse gene were
then paired with the fragments derived from the human gene based on their
homology. Within the 300-bp matching frames, 50-bp regions from the
mouse gene were compared with 50-bp regions in the human gene, and the
location with the highest percentage homology was reported. The highest
percentage homology of a region is reported in Fig. 4B. The same approach
was used for comparing the mouse and rat copies of Ptpn1.
ChIP. CD4 T cells were isolated as described above and incubated overnight in
testosterone-free media. T cells were then treated in triplicate with 2 ng/mL
R1881 or DMSO as a vehicle control for 12 h. Samples were pooled after 12 h,
and ChIP was performed using the Cell Signaling enzymatic preparation kit
(cat# 9003) (see Table S1 for specific information).
Statistical Analysis. Statistical analysis was performed using the Student t test.
P < 0.05 was considered significant.
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